116 related articles for article (PubMed ID: 36602428)
21. METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment.
Wang L; Peng JL
Sci Rep; 2023 Jul; 13(1):10755. PubMed ID: 37400463
[TBL] [Abstract][Full Text] [Related]
22. TREM2
Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
[TBL] [Abstract][Full Text] [Related]
23. The ubiquitin-specific protease 5 mediated deubiquitination of LSH links metabolic regulation of ferroptosis to hepatocellular carcinoma progression.
Yan B; Guo J; Wang Z; Ning J; Wang H; Shu L; Hu K; Chen L; Shi Y; Zhang L; Liu S; Tao Y; Xiao D
MedComm (2020); 2023 Aug; 4(4):e337. PubMed ID: 37492786
[TBL] [Abstract][Full Text] [Related]
24. NUSAP1-LDHA-Glycolysis-Lactate feedforward loop promotes Warburg effect and metastasis in pancreatic ductal adenocarcinoma.
Chen M; Cen K; Song Y; Zhang X; Liou YC; Liu P; Huang J; Ruan J; He J; Ye W; Wang T; Huang X; Yang J; Jia Y; Liang X; Shen P; Wang Q; Liang T
Cancer Lett; 2023 Jul; 567():216285. PubMed ID: 37354982
[TBL] [Abstract][Full Text] [Related]
25. Roles and implications of mRNA N
Zeng L; Huang X; Zhang J; Lin D; Zheng J
Cancer Commun (Lond); 2023 Jul; 43(7):729-748. PubMed ID: 37350762
[TBL] [Abstract][Full Text] [Related]
26. Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression.
Wang S; Zhou L; Ji N; Sun C; Sun L; Sun J; Du Y; Zhang N; Li Y; Liu W; Lu W
Drug Resist Updat; 2023 Jul; 69():100976. PubMed ID: 37210811
[TBL] [Abstract][Full Text] [Related]
27. Deubiquitinase USP13 regulates glycolytic reprogramming and progression in osteosarcoma by stabilizing METTL3/m
Wang C; Meng Y; Zhao J; Ma J; Zhao Y; Gao R; Liu W; Zhou X
Int J Biol Sci; 2023; 19(7):2289-2303. PubMed ID: 37151889
[TBL] [Abstract][Full Text] [Related]
28. USP5 knockdown alleviates lung cancer progression via activating PARP1-mediated mTOR signaling pathway.
Cao L; Liu H; Huang C; Guo C; Zhao L; Gao C; Xu Y; Wang G; Liang N; Li S
Biol Direct; 2023 Apr; 18(1):16. PubMed ID: 37060095
[TBL] [Abstract][Full Text] [Related]
29. N6-methyladenosine (m6A) modification of ribosomal RNAs (rRNAs): Critical roles in mRNA translation and diseases.
Lei K; Lin S; Yuan Q
Genes Dis; 2023 Jan; 10(1):126-134. PubMed ID: 37013049
[TBL] [Abstract][Full Text] [Related]
30. N
Chen B; Huang Y; He S; Yu P; Wu L; Peng H
Cell Chem Biol; 2023 Feb; 30(2):144-158.e10. PubMed ID: 36800991
[TBL] [Abstract][Full Text] [Related]
31. Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy.
Afonso J; Gonçalves C; Costa M; Ferreira D; Santos L; Longatto-Filho A; Baltazar F
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765947
[TBL] [Abstract][Full Text] [Related]
32. RNA m6A methylation across the transcriptome.
Sendinc E; Shi Y
Mol Cell; 2023 Feb; 83(3):428-441. PubMed ID: 36736310
[TBL] [Abstract][Full Text] [Related]
33. EOAI, a ubiquitin-specific peptidase 5 inhibitor, prevents non-small cell lung cancer progression by inducing DNA damage.
Zheng Y; Wang L; Niu X; Guo Y; Zhao J; Li L; Zhao J
BMC Cancer; 2023 Jan; 23(1):28. PubMed ID: 36611139
[TBL] [Abstract][Full Text] [Related]
34. METTL5 promotes gastric cancer progression
Zhang YQ; Li J; Qin Z; Li DM; Ye FZ; Bei SH; Zhang XH; Feng L
World J Gastrointest Oncol; 2024 May; 16(5):1925-1946. PubMed ID: 38764837
[TBL] [Abstract][Full Text] [Related]
35. METTL5 promotes cell proliferation, invasion, and migration by up-regulating Toll-like receptor 8 expression in colorectal cancer.
Kong LS; Tao R; Li YF; Wang WB; Zhao X
World J Gastrointest Oncol; 2024 May; 16(5):2006-2017. PubMed ID: 38764815
[TBL] [Abstract][Full Text] [Related]
36. The m6A methyltransferase METTL5 promotes neutrophil extracellular trap network release to regulate hepatocellular carcinoma progression.
Wang Q; Huang Y; Zhu Y; Zhang W; Wang B; Du X; Dai Q; Zhang F; Fang Z
Cancer Med; 2024 Apr; 13(7):e7165. PubMed ID: 38613157
[TBL] [Abstract][Full Text] [Related]
37. Targeting RNA modifications with pharmacological agents: New frontiers in cancer therapy.
Guan A; Wong JJ
Cancer Med; 2024 Apr; 13(7):e6989. PubMed ID: 38545841
[TBL] [Abstract][Full Text] [Related]
38. Lipid metabolism-related long noncoding RNA RP11-817I4.1 promotes fatty acid synthesis and tumor progression in hepatocellular carcinoma.
Wang RY; Yang JL; Xu N; Xu J; Yang SH; Liang DM; Li JZ; Zhu H
World J Gastroenterol; 2024 Feb; 30(8):919-942. PubMed ID: 38516243
[TBL] [Abstract][Full Text] [Related]
39. ENO2 promotes anoikis resistance in anaplastic thyroid cancer by maintaining redox homeostasis.
Zhang Y; Ji X; Wang Y
Gland Surg; 2024 Feb; 13(2):209-224. PubMed ID: 38455357
[TBL] [Abstract][Full Text] [Related]
40. Beta-Cell Tipe1 Orchestrates Insulin Secretion and Cell Proliferation by Promoting Gαs/cAMP Signaling via USP5.
Ding L; Sun Y; Liang Y; Zhang J; Fu Z; Ren C; Li P; Liu W; Xiao R; Wang H; Zhang Z; Yue X; Li C; Wu Z; Feng Y; Liang X; Ma C; Gao L
Adv Sci (Weinh); 2024 Apr; 11(16):e2304940. PubMed ID: 38417114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
